Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer

While progesterone receptor (PR)-targeted therapies are modestly active in patients with uterine cancer, their underlying molecular mechanisms are not well understood. The clinical use of such therapies is limited because of the lack of biomarkers that predict response to PR-agonists (progestins) or...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Main Authors: Huang, Yan, Hu, Wei, Huang, Jie, Shen, Fangrong, Sun, Yunjie, Ivan, Cristina, Pradeep, Sunila, Dood, Robert, Haemmerle, Monika, Jiang, Dahai, Mangala, Lingegowda S., Noh, Kyunghee, Hansen, Jean M, Dalton, Heather J., Previs, Rebecca A., Nagaraja, Archana S., McGuire, Michael, Jennings, Nicholas B., Broaddus, Russell, Coleman, Robert L., Sood, Anil K.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805630/
https://ncbi.nlm.nih.gov/pubmed/29237804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0006
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares